The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease
- 273 Downloads
The prognostic value of regadenoson SPECT myocardial perfusion imaging (MPI) has not been specifically studied in patients with end-stage renal disease (ESRD).
Methods and Results
We prospectively followed ESRD patients enrolled in the ASSUAGE and ASSUAGE-CKD trials in which they received regadenoson-stress 99mTc-tetrofosmin SPECT-MPI. Images were semiquantitatively analyzed by an investigator blinded to clinical and outcome data. Patients were followed for cardiac death, myocardial infarction (MI), and coronary revascularization (CR). Revascularizations occurring >90 days post-MPI were considered “late” events. Survival analysis was performed using Cox regression models, adjusting for age, gender, diabetes, dyslipidemia, smoking, and known coronary artery disease. We analyzed 303 patients (mean age 54 years; 64% men), who were followed for 35 ± 10 months. Adjusting for clinical covariates, abnormal regadenoson-stress MPI (SSS ≥ 4) was associated with increased risk of the composite of cardiac death or MI (23.9% vs 14.4%; HR 1.88; CI 1.04-3.41; P = .037) and the composite of cardiac death, MI, or late CR (27.3% vs 16.7%; HR 1.80; CI 1.03-3.14; P = .039). Adjusting for clinical covariates, regadenoson-induced myocardial ischemia (SDS ≥ 2) was associated with increased rate of the composite endpoint of cardiac death, MI, or CR (33.3% vs 16.9%; HR 1.97; CI 1.19-3.27; P = .008).
Regadenoson-stress SPECT-MPI provides a significant prognostic value in patients with ESRD. ESRD patients with normal SPECT-MPI have relatively high adverse event rates.
KeywordsRegadenoson myocardial perfusion imaging (MPI) end-stage renal disease (ESRD) coronary artery disease prognosis outcome
Coronary artery disease
End-stage renal disease
Myocardial perfusion abnormality
Summed difference score
Single-photon emission computed tomography
Summed stress score
Transient ischemic dilation
Rami Doukky serves on the Advisory Board for Astellas Pharma and receives research funding from Astellas Pharma. Other authors have no conflicts to report.
- 3.AMR/Arlington Medical Resources Inc. Myocardial Study Market Guide, Jan-Jun 2012; 2012.Google Scholar
- 4.Astellas Pharma US. Lexiscan; 2015.Google Scholar
- 7.Rangel MO, Morales Demori R, Voll ST, Wassouf M, Dick R, Doukky R. Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: A substudy of the ASSUAGE and ASSUAGE-CKD trials. J Nucl Cardiol. 2015;22:1008–18.CrossRefPubMedGoogle Scholar
- 14.Lentine KL, Costa SP, Weir MR, Robb JF, Fleisher LA, Kasiske BL, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2012;60:434–80.CrossRefPubMedGoogle Scholar
- 15.Doukky R, MoralesDemori R, Jain S, Kiriakos R, Mwansa V, Calvin JE. Attenuation of the side effect profile of regadenoson: A randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. “The ASSUAGE trial”. J Nucl Cardiol. 2012;19:448–57.CrossRefPubMedGoogle Scholar
- 16.Doukky R, Rangel MO, Dick R, Wassouf M, Alqaid A, Margeta B. Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease—the ASSUAGE-CKD trial. Int J Cardiovasc Imaging. 2013;29:1029–37.CrossRefPubMedGoogle Scholar
- 19.Ballany W, Mansour K, MoralesDemori R, Al-Amoodi M, Doukky R. The impact of regimented aminophylline use on extracardiac radioisotope activity in patients undergoing regadenoson stress SPECT myocardial perfusion imaging: A substudy of the ASSUAGE trial. J Nucl Cardiol. 2014;21:496–502.CrossRefPubMedGoogle Scholar
- 20.Golzar Y, Olusanya A, Pe N, Dua SG, Golzar J, Gidea C, et al. The significance of automatically measured transient ischemic dilation in identifying severe and extensive coronary artery disease in regadenoson, single-isotope technetium-99 m myocardial perfusion SPECT. J Nucl Cardiol. 2015;22:526–34.CrossRefPubMedGoogle Scholar
- 21.Doukky R, Frogge N, Bayissa YA, Balakrishnan G, Skelton JM, Confer K, et al. The prognostic value of transient ischemic dilatation with otherwise normal SPECT myocardial perfusion imaging: A cautionary note in patients with diabetes and coronary artery disease. J Nucl Cardiol. 2013;20:774–84.CrossRefPubMedGoogle Scholar